On February 1, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the successful closing of its public offering, which was previously disclosed. The offering included 4,375,000 shares of common stock or pre-funded warrants and two classes of warrants to purchase up to 8,750,000 shares of common stock. The offering was priced at $2.06 per share and associated Public Warrants, and $2.059 per pre-funded warrant and associated Public Warrants. The gross proceeds from the offering amounted to approximately $9.0 million, before deducting placement agent fees and other offering expenses. Panbela intends to use the net proceeds for clinical development of its product candidates, working capital, business development, and other corporate purposes, which may include debt repayment. Following the offering, Panbela had 3,481,298 shares of common...Show More

On February 1, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the successful closing of its public offering, which was previously disclosed. The offering included 4,375,000 shares of common stock or pre-funded warrants and two classes of warrants to purchase up to 8,750,000 shares of common stock. The offering was priced at $2.06 per share and associated Public Warrants, and $2.059 per pre-funded warrant and associated Public Warrants. The gross proceeds from the offering amounted to approximately $9.0 million, before deducting placement agent fees and other offering expenses. Panbela intends to use the net proceeds for clinical development of its product candidates, working capital, business development, and other corporate purposes, which may include debt repayment. Following the offering, Panbela had 3,481,298 shares of common stock issued and outstanding as of January 31, 2024. Roth Capital Partners served as the sole placement agent for the offering. The securities were offered pursuant to a registration statement that was declared effective by the SEC on January 26, 2024. Panbela's common stock is traded on The Nasdaq Stock Market under the symbol 'PBLA'.